Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Concord Biotech Ltd. (CONCORDBIO) Stock Price & Analysis

4 Followers

CONCORDBIO Stock Chart & Stats

₹596.85-₹35.30(-5.58%)
At close: 3:30 PM GMT+5:30
₹600₹700₹800Aug 17Aug 31Sep 15Sep 28Oct 12Oct 26Nov 9
Day’s Range
INR 592.85 - INR 632.20
52-Week Range
INR 493.53 - INR 807.03
Previous Close
INR 632.15
Volume
N/A
Average Volume (3M)
20.93K
Market Cap
INR 124.88B
Enterprise Value
INR 139.20B
Total Cash (Recent Filing)
INR 4.32B
Total Debt (Recent Filing)
INR 0
Price to Earnings (P/E)
44.3
Beta
0.83
Next Earnings
Feb 18, 2027 (Est.)
EPS Estimate
N/A
Last Dividend Ex-Date
Jul 24, 2026
Dividend Yield
1.27%

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet

Minimal leverage reduces financial risk and preserves flexibility for investment, shareholder returns, or resilience during weaker operating periods. Steadily rising equity also indicates that the company has strengthened its capital base while maintaining consistently positive returns on equity.

Strong Operating Cash Generation

Consistently positive operating cash flow that generally exceeds net income supports the quality of reported earnings and provides internally generated funding. This strengthens the company’s ability to sustain operations and finance development without relying heavily on external capital.

Durable Profitability

Healthy gross, net, EBIT, and EBITDA margins show that the business has retained meaningful profitability across the reported period. This provides an earnings cushion and suggests its specialized fermentation-based portfolio can support attractive economics over the medium term.

Bears Say

Revenue Contraction

The 2026 annual revenue decline interrupts the company’s prior expansion pattern and raises concern about the durability of demand growth. If this persists, slower scale benefits could limit earnings progression and reduce the resources available for investment in future products.

Margin Compression

Margin compression alongside lower net income indicates that profitability has normalized from unusually strong earlier levels. A sustained reduction in operating profitability would weaken earnings conversion and make future growth less valuable, even with the company’s conservative balance sheet.

Free Cash Flow Volatility

Although free cash flow rebounded strongly in 2026, its history includes a negative year and a later decline, showing that cash available after investment can fluctuate materially. Such variability may complicate long-term planning and reduce consistency in funding growth or distributions.

Concord Biotech Ltd. News

CONCORDBIO FAQ

What was Concord Biotech Ltd.’s price range in the past 12 months?
Concord Biotech Ltd. lowest stock price was ₹493.53 and its highest was ₹807.03 in the past 12 months.
What is Concord Biotech Ltd.’s market cap?
Concord Biotech Ltd.’s market cap is ₹124.88B.
When is Concord Biotech Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Concord Biotech Ltd.’s earnings last quarter?
Concord Biotech Ltd. released its earnings results on Oct 27, 2026. The company reported ₹3.4 earnings per share for the quarter, missing the consensus estimate of ₹3.517 by -₹0.117.
Is Concord Biotech Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Concord Biotech Ltd. pay dividends?
Concord Biotech Ltd. pays an annual dividend of ₹7.55 which represents an annual dividend yield of 1.27%. See more information on Concord Biotech Ltd. dividends here
What is Concord Biotech Ltd.’s EPS estimate?
Concord Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Concord Biotech Ltd. have?
Concord Biotech Ltd. has 209,232,400 shares outstanding.
What happened to Concord Biotech Ltd.’s price movement after its last earnings report?
Concord Biotech Ltd. reported an EPS of ₹3.4 in its last earnings report, missing expectations of ₹3.517. Following the earnings report the stock price went up 5.516%.
Which hedge fund is a major shareholder of Concord Biotech Ltd.?
Currently, no hedge funds are holding shares in IN:CONCORDBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology